NASDAQ · GALT
Healthcare · Biotechnology
$3.35
Up+$0.02 (+0.60%)
Updated Nov 4, 2026, 5:08 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · GALT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
GALT closed at $3.35 after 21 trading sessions, down 10.90% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $3.33 | $3.4999 | $3.33 | $3.35 | 118.39K |
| Nov 2, 2026 | $3.35 | $3.43 | $3.29 | $3.33 | 117.17K |
| Oct 30, 2026 | $3.52 | $3.5414 | $3.27 | $3.32 | 174.75K |
| Oct 29, 2026 | $3.61 | $3.70 | $3.4477 | $3.52 | 263.87K |
| Oct 28, 2026 | $3.37 | $3.56 | $3.27 | $3.54 | 141.16K |
| Oct 27, 2026 | $3.21 | $3.44 | $3.13 | $3.38 | 204.73K |
| Oct 26, 2026 | $3.22 | $3.255 | $3.11 | $3.19 | 164.39K |
| Oct 23, 2026 | $3.35 | $3.37 | $3.16 | $3.19 | 195.22K |
| Oct 22, 2026 | $3.34 | $3.50 | $3.27 | $3.38 | 161.54K |
| Oct 21, 2026 | $3.46 | $3.51 | $3.19 | $3.37 | 295.69K |
| Oct 20, 2026 | $3.51 | $3.615 | $3.41 | $3.43 | 200.2K |
| Oct 19, 2026 | $3.60 | $3.7256 | $3.47 | $3.495 | 177.29K |
| Oct 16, 2026 | $3.71 | $3.81 | $3.61 | $3.62 | 169.43K |
| Oct 15, 2026 | $3.68 | $3.84 | $3.66 | $3.71 | 119.2K |
| Oct 14, 2026 | $3.66 | $3.86 | $3.61 | $3.64 | 408.98K |
| Oct 13, 2026 | $3.84 | $3.86 | $3.67 | $3.69 | 184.92K |
| Oct 12, 2026 | $3.92 | $4.005 | $3.84 | $3.87 | 99.68K |
| Oct 9, 2026 | $3.64 | $3.97 | $3.64 | $3.94 | 156.51K |
| Oct 8, 2026 | $3.62 | $3.69 | $3.5101 | $3.64 | 270.89K |
| Oct 7, 2026 | $3.74 | $3.86 | $3.59 | $3.62 | 176.02K |
| Oct 6, 2026 | $3.75 | $3.79 | $3.57 | $3.76 | 277.93K |
The latest Smart Investors Daily articles mentioning GALT.
Company
Market Activity
Research & News
GALT research
Company profile and research snapshot.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 23, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 17, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 2, 2025 | HC Wainwright & Co. | Neutral | — |
| Dec 27, 2024 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
Benzinga · Feb 26, 2026
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader
SeekingAlpha · Dec 4, 2025
Galectin Therapeutics (GALT) is building momentum on positive NAVIGATE trial data for belapectin, targeting compensated MASH cirrhosis.
seekingalpha.com · Dec 4, 2025
Galectin Therapeutics (GALT) is building momentum on positive NAVIGATE trial data for belapectin, targeting compensated MASH cirrhosis. GALT reported a narrower Q3 loss due to lower R&D and operating expenses post-trial, with a cash runway through mid-2026 after securing a $10M credit line. Belapectin demonstrated reductions in liver stiffness, fibrogenesis, and new varices, especially in high-risk patients, while maintaining a favorable safety profile.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GALT.
